Lyell Immunopharma, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: -52.3%
EBITDA: -20.2%
EBIT: +46.8%
EPS: —
Free cash flow: +23.5%
Operating cash flow: +23.6%

Forward estimates

Revenue: -7.5%
EBITDA: +100.0%
EPS: +69.2%

Three-year CAGR

Revenue: -92.5%
EBITDA: -31.0%
EBIT: +43.2%
Net income: +20.0%
EPS: —
Free cash flow: +7.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.